Remepy
Remepy57
About
What does Remepy do?
Remepy pioneers Hybrid Drugs, a new class of medicine integrating pharmaceutical molecules with AI-driven digital protocols delivered via app. These Hybrid Drugs measurably improve motor, cognitive, and mental function, with their first product, Hybridopa, targeting Parkinson's Disease. Remepy's approach is regulated like medicine, adaptive like software, and reimbursed like pharma, aiming to deliver superior outcomes.
What is Remepy's revenue?
StartupHub estimates Remepy's annual revenue at $14.1M (range $8.9M to $20.8M, 66% confidence), based on comparable companies in the sector.
What is Remepy's valuation?
StartupHub estimates Remepy's effective valuation at $60.9M (range $37.5M to $90.0M, 15% confidence), based on comparable companies in the sector.
How much funding has Remepy raised?
Remepy has raised a total of $15M in funding. The most recent round on record is Seed.
Where is Remepy headquartered?
Remepy is headquartered in Tel Aviv, Israel.
When was Remepy founded?
Remepy was founded in 2021.
What industry does Remepy operate in?
Remepy operates in Healthcare, Drug Development, Biotech, Life Sciences, HealthTech, MedTech.
How many employees does Remepy have?
Remepy has approximately 75 people on record.
No comments yet. Be the first to share your take.